New HCPCS Code for Portrazza® (Necitumumab)

We are sending this communication on behalf of Eli Lilly and Company to announce the assignment of a product‐specific Healthcare Common Procedure Coding System (HCPCS) code for Portrazza® (necitumumab) for injection.

                       

The new code, J9295, is defined as “injection, necitumumab, 1 mg.” This code is effective January 1, 2017.1   

Trade Name HCPCS Code Strength NDC* Effective Date
Portrazza J9295 injection, necitumumab, 1 mg 800 mg/50 mL (16 mg/mL) 00002-7716-01 January 1, 2017

*Note that the product’s NDC code has been “zero‐filled” to ensure creation of an 11‐digit code that meets CMS standards.

The zero‐fill location is indicated in bold.
NDC=National Drug Code.

Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.

WARNING: CARDIOPULMONARY ARREST and HYPOMAGNESEMIA

·         Cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with Portrazza in combination with gemcitabine and cisplatin. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after Portrazza administration.

·         Hypomagnesemia occurred in 83% of patients receiving Portrazza in combination with gemcitabine and cisplatin, and was severe in 20% of patients. Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of Portrazza during treatment and for at least 8 weeks following completion of Portrazza. Withhold Portrazza for grade 3 or 4 electrolyte abnormalities. Replete electrolytes as medically appropriate.

For more information, please visit www.Portrazza.com/hcp.



No comments have been posted yet.